NASDAQ:MCRB

Seres Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy MCRB

*Your capital is at risk

$7.05

+0.450 (+6.82%)

At Close: Jun 23, 2026

Seres Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 78.04. In total, the insiders bought 387.98K and sold 4.36K MCRB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	78.04
● Buy	387.98K shares
● Sell	4.36K shares
81% Buy Activity Weak Negative Correlation
Buy Signal High Confidence Mar 04, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 78.04. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (81% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 18, 2026 Sell	Common Stock S-Sale	Henn Matthew R See Remarks	Officer	77 Value: $580
May 18, 2026 Sell	Common Stock S-Sale	Shaff Eric D. Director	Director	259 Value: $2K
May 18, 2026 Sell	Common Stock S-Sale	Desrosier Thomas See Remarks	Officer	79 Value: $595
May 18, 2026 Sell	Common Stock S-Sale	Brady Kelly See Remarks	Officer	59 Value: $444
May 15, 2026 Buy	Restricted Stock Units M-Exempt	Brady Kelly See Remarks	Officer	89 Value: $680
May 15, 2026 Buy	Restricted Stock Units M-Exempt	Brady Kelly See Remarks	Officer	91 Value: $695
May 15, 2026 Buy	Restricted Stock Units M-Exempt	Desrosier Thomas See Remarks	Officer	111 Value: $848
May 15, 2026 Buy	Restricted Stock Units M-Exempt	Shaff Eric D. Director	Director	391 Value: $3K
May 15, 2026 Buy	Common Stock M-Exempt	Desrosier Thomas See Remarks	Officer	244 Value: $2K
May 15, 2026 Buy	Common Stock M-Exempt	Shaff Eric D. Director	Director	722 Value: $6K
May 15, 2026 Buy	Restricted Stock Units M-Exempt	Shaff Eric D. Director	Director	331 Value: $3K
May 15, 2026 Buy	Restricted Stock Units M-Exempt	Desrosier Thomas See Remarks	Officer	133 Value: $1K
May 15, 2026 Buy	Common Stock M-Exempt	Brady Kelly See Remarks	Officer	180 Value: $1K
May 15, 2026 Buy	Common Stock M-Exempt	Henn Matthew R See Remarks	Officer	238 Value: $2K
May 15, 2026 Buy	Restricted Stock Units M-Exempt	Henn Matthew R See Remarks	Officer	97 Value: $741
May 15, 2026 Buy	Restricted Stock Units M-Exempt	Henn Matthew R See Remarks	Officer	141 Value: $1K
Mar 04, 2026 Buy	Stock Option (right to buy) A-Award	Brady Kelly See Remarks	Officer	56 250 Value: $513.6K
Mar 04, 2026 Buy	Stock Option (right to buy) A-Award	Desrosier Thomas See Remarks	Officer	22 500 Value: $205.4K
Mar 04, 2026 Buy	Stock Option (right to buy) A-Award	Thorell Marella See Remarks	Officer	22 500 Value: $205.4K
Mar 04, 2026 Buy	Stock Option (right to buy) A-Award	Henn Matthew R See Remarks	Officer	75 000 Value: $684.8K
Mar 04, 2026 Buy	Stock Option (right to buy) A-Award	Kender Richard N See Remarks	Officer	150 000 Value: $1.37M
Mar 02, 2026 Buy	Stock Option (right to buy)	Brady Kelly See Remarks	Officer	1 430 Value: $32.9K
Mar 02, 2026 Buy	Restricted Stock Units	Brady Kelly See Remarks	Officer	730 Value: $7K
Mar 02, 2026 Buy	Common Stock	Brady Kelly See Remarks	Officer	0 Value: $0
Mar 02, 2026 Buy	Stock Option (right to buy)	Brady Kelly See Remarks	Officer	2 925 Value: $64.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SERES THERAPEUTICS

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteri...

Read Full Profile Here